Morgan Stanley’s Purple Biotech PPBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.33K | Sell |
578
-31
| -5% | -$167 | ﹤0.01% | 7303 |
|
|
2025
Q4 | $4K | Sell |
609
-498
| -45% | -$3.61K | ﹤0.01% | 7106 |
|
|
2025
Q3 | $6.36K | Buy |
1,107
+650
| +142% | +$11.7K | ﹤0.01% | 7029 |
|
|
2025
Q2 | $10.7K | Buy |
457
+10
| +2% | +$247 | ﹤0.01% | 6844 |
|
|
2025
Q1 | $11.9K | Sell |
447
-65
| -13% | -$2.08K | ﹤0.01% | 6745 |
|
|
2024
Q4 | $24K | Sell |
512
-294
| -36% | -$11.3K | ﹤0.01% | 6512 |
|
|
2024
Q3 | $44.7K | Sell |
806
-209
| -21% | -$15.8K | ﹤0.01% | 6253 |
|
|
2024
Q2 | $82.6K | Buy |
1,015
+332
| +49% | +$38.5K | ﹤0.01% | 6030 |
|
|
2024
Q1 | $91.5K | Sell |
683
-182
| -21% | -$26.1K | ﹤0.01% | 6028 |
|
|
2023
Q4 | $135K | Buy |
865
+713
| +469% | +$158K | ﹤0.01% | 6069 |
|
|
2023
Q3 | $36.2K | Buy |
152
+4
| +3% | +$953 | ﹤0.01% | 6298 |
|
|
2023
Q2 | $41.3K | Buy |
148
+33
| +29% | +$11.8K | ﹤0.01% | 6288 |
|
|
2023
Q1 | $41.3K | Buy |
115
+6
| +6% | +$2.25K | ﹤0.01% | 6350 |
|
|
2022
Q4 | $30.2K | Buy |
109
+28
| +35% | +$10.7K | ﹤0.01% | 6516 |
|
|
2022
Q3 | $33K | Sell |
81
-3
| -4% | -$1.4K | ﹤0.01% | 6582 |
|
|
2022
Q2 | $40K | Buy |
84
+45
| +115% | +$26.9K | ﹤0.01% | 6706 |
|
|
2022
Q1 | $31K | Sell |
39
-78
| -67% | -$50.3K | ﹤0.01% | 6942 |
|
|
2021
Q4 | $91K | Sell |
117
-1
| -0.8% | -$852 | ﹤0.01% | 6497 |
|
|
2021
Q3 | $108K | Sell |
118
-72
| -38% | -$69.7K | ﹤0.01% | 6323 |
|
|
2021
Q2 | $185K | Sell |
190
-649
| -77% | -$596K | ﹤0.01% | 6057 |
|
|
2021
Q1 | $693K | Sell |
839
-1,635
| -66% | -$1.53M | ﹤0.01% | 4965 |
|
|
2020
Q4 | $1.89M | Buy |
2,474
+2,443
| +7,881% | +$2.06M | ﹤0.01% | 4212 |
|
|
2020
Q3 | $27K | Buy |
31
+30
| +3,000% | +$37.1K | ﹤0.01% | 5945 |
|
|
2020
Q2 | $2K | Sell |
1
-278
| -100% | -$273K | ﹤0.01% | 6459 |
|
|
2020
Q1 | $171K | Buy |
279
+245
| +721% | +$300K | ﹤0.01% | 4932 |
|
|
2019
Q4 | $53K | Buy |
34
+20
| +143% | +$29.2K | ﹤0.01% | 5837 |
|
|
2019
Q3 | $20K | Sell |
14
-15
| -52% | -$25.1K | ﹤0.01% | 6017 |
|
|
2019
Q2 | $55K | Buy |
29
+13
| +81% | +$25.9K | ﹤0.01% | 5565 |
|
|
2019
Q1 | $39K | Buy |
16
+15
| +1,500% | +$36.1K | ﹤0.01% | 5772 |
|
|
2018
Q4 | $2K | Sell |
1
-1
| -50% | -$2.52K | ﹤0.01% | 6426 |
|
|
2018
Q3 | $5K | Sell |
2
-22
| -92% | -$87K | ﹤0.01% | 6449 |
|
|
2018
Q2 | $128K | Buy |
+24
| New | +$120K | ﹤0.01% | 5677 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 6547 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 6615 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 6672 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 6754 |
|
Other funds holding PPBT
SP
GI
SS
ASN
Morgan Stanley's PPBT Position: Q1 2026 in Review
Morgan Stanley reduced its Purple Biotech (PPBT) stake by 5.1% in Q1 2026, selling an estimated $167 and leaving 578 shares worth $2.33K. The position accounts for ﹤0.01% of the portfolio, ranked #7303.
Morgan Stanley first reported a position in PPBT in Q2 2018 and has held it in 32 quarters since. The position peaked at $1.89M in Q4 2020. 15 funds tracked by Wall St. Rank hold PPBT as of Q1 2026.
- Morgan Stanley held 578 shares of Purple Biotech worth $2.33K as of Q1 2026.
- Morgan Stanley sold 31 Purple Biotech shares in Q1 2026, an estimated $167.
- Purple Biotech made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7303 holding.
- Morgan Stanley first reported a position in Purple Biotech in Q2 2018 and has held it in 32 quarters since.
- Morgan Stanley's Purple Biotech position peaked at $1.89M in Q4 2020.
- 15 funds tracked by Wall St. Rank held Purple Biotech as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.